+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Antidiabetic Drug Market Research Report by Patient, by Disease, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19

  • ID: 5264372
  • Report
  • July 2021
  • Region: Global
  • 181 pages
  • 360iResearch™
UP TO OFF
until Sep 30th 2021
The Global Antidiabetic Drug Market will Grow to USD 64.48 Billion by 2026, at a CAGR of 10.56%

FEATURED COMPANIES

  • Abbott Laboratories
  • AstraZeneca PLC
  • Cipla, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Mankind Pharma Ltd
  • Novo Nordisk A/S
The Global Antidiabetic Drug Market size was estimated at USD 35.29 Billion in 2020 and expected to reach USD 38.90 Billion in 2021, at a Compound Annual Growth Rate (CAGR) 10.56% to reach USD 64.48 Billion by 2026.



Market Statistics:


The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:


This research report categorizes the Antidiabetic Drug to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Patient, the Antidiabetic Drug Market was studied across Adult, Geriatric, and Pediatric.
  • Based on Type, the Antidiabetic Drug Market was studied across Alpha-glucosidase Inhibitors, Biguanides, DPP-IV (Dipeptidyl Peptidase) Inhibitors, GLP-1 (Glucagon-like Peptide) Agonists, Insulin, Meglitinides, SGLT-II (Sodium Glucose Transport Proteins) Inhibitors, Sulphonylureas, and Thiazolidinedione. The Insulin is further studied across Intermediate-acting Insulin, Long-acting Analog, Premixed Insulin, Rapid-acting Analog, and Short-acting Analog.
  • Based on Disease, the Antidiabetic Drug Market was studied across Diabetes Mellitus Type 1 and Diabetes Mellitus Type 2.
  • Based on Region, the Antidiabetic Drug Market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:


COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:


The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:


The FPNV Positioning Matrix evaluates and categorizes the vendors in the Antidiabetic Drug Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:


The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Company Usability Profiles:


The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Antidiabetic Drug Market, including Abbott Laboratories, Aristo Pharmaceuticals Pvt. Ltd., Astellas Pharma Inc., AstraZeneca PLC, Biocon Limited, C.H. Boehringer Sohn AG & Co. KG, Cadila Pharmaceuticals Limited, Cipla, Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Glenmark Pharmaceuticals Ltd., Halozyme Therapeutics, Inc., Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals), Mankind Pharma Ltd, Merck KGaA, Novo Nordisk A/S, Oramed Pharmaceuticals Inc., Pfizer Inc., PHC Corporation, Sanofi S.A., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., TONGHUA DONGBAO PHARMACEUTICAL CO., LTD., and Wockhardt Limited.

The report provides insights on the following pointers:


1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:


1. What is the market size and forecast of the Global Antidiabetic Drug Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Antidiabetic Drug Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Antidiabetic Drug Market?
4. What is the competitive strategic window for opportunities in the Global Antidiabetic Drug Market?
5. What are the technology trends and regulatory frameworks in the Global Antidiabetic Drug Market?
6. What is the market share of the leading vendors in the Global Antidiabetic Drug Market?
7. What modes and strategic moves are considered suitable for entering the Global Antidiabetic Drug Market?
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories
  • AstraZeneca PLC
  • Cipla, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Mankind Pharma Ltd
  • Novo Nordisk A/S
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary
3.1. Introduction
3.2. Market Outlook
3.3. Patient Outlook
3.4. Type Outlook
3.5. Disease Outlook
3.6. Region Outlook
3.7. Competitor Outlook

4. Market Overview
4.1. Introduction
4.2. Cumulative Impact of COVID-19

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Changing lifestyle of people and irregular dietary habits
5.1.1.2. Strong product pipeline of antidiabetics
5.1.1.3. Globally rising prevalence of diabetes and increasing obesity among people
5.1.1.4. Increasing consumer awareness level and improved technology
5.1.2. Restraints
5.1.2.1. Prohibitive cost of Insulin
5.1.3. Opportunities
5.1.3.1. Advancement in the healthcare and pharmaceutical sectors
5.1.3.2. Ongoing research and development
5.1.3.3. Governments and private companies to work together for the supply of inexpensive drugs
5.1.4. Challenges
5.1.4.1. Wide availability of antidiabetics drugs
5.2. Porters Five Forces Analysis
5.2.1. Threat of New Entrants
5.2.2. Threat of Substitutes
5.2.3. Bargaining Power of Customers
5.2.4. Bargaining Power of Suppliers
5.2.5. Industry Rivalry

6. Antidiabetic Drug Market, by Patient
6.1. Introduction
6.2. Adult
6.3. Geriatric
6.4. Pediatric

7. Antidiabetic Drug Market, by Type
7.1. Introduction
7.2. Alpha-glucosidase Inhibitors
7.3. Biguanides
7.4. DPP-IV (Dipeptidyl Peptidase) Inhibitors
7.5. GLP-1 (Glucagon-like Peptide) Agonists
7.6. Insulin
7.6.1. Intermediate-acting Insulin
7.6.2. Long-acting Analog
7.6.3. Premixed Insulin
7.6.4. Rapid-acting Analog
7.6.5. Short-acting Analog
7.7. Meglitinides
7.8. SGLT-II (Sodium Glucose Transport Proteins) Inhibitors
7.9. Sulphonylureas
7.10. Thiazolidinedione

8. Antidiabetic Drug Market, by Disease
8.1. Introduction
8.2. Diabetes Mellitus Type 1
8.3. Diabetes Mellitus Type 2

9. Americas Antidiabetic Drug Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Antidiabetic Drug Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Thailand

11. Europe, Middle East & Africa Antidiabetic Drug Market
11.1. Introduction
11.2. France
11.3. Germany
11.4. Italy
11.5. Netherlands
11.6. Qatar
11.7. Russia
11.8. Saudi Arabia
11.9. South Africa
11.10. Spain
11.11. United Arab Emirates
11.12. United Kingdom

12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion

13. Company Usability Profiles
13.1. Abbott Laboratories
13.2. Aristo Pharmaceuticals Pvt. Ltd.
13.3. Astellas Pharma Inc.
13.4. AstraZeneca PLC
13.5. Biocon Limited
13.6. C.H. Boehringer Sohn AG & Co. KG
13.7. Cadila Pharmaceuticals Limited
13.8. Cipla, Inc.
13.9. Eli Lilly and Company
13.10. F. Hoffmann-La Roche Ltd.
13.11. GlaxoSmithKline PLC
13.12. Glenmark Pharmaceuticals Ltd.
13.13. Halozyme Therapeutics, Inc.
13.14. Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals)
13.15. Mankind Pharma Ltd
13.16. Merck KGaA
13.17. Novo Nordisk A/S
13.18. Oramed Pharmaceuticals Inc.
13.19. Pfizer Inc.
13.20. PHC Corporation
13.21. Sanofi S.A.
13.22. Takeda Pharmaceutical Company Limited
13.23. Teva Pharmaceutical Industries Ltd.
13.24. TONGHUA DONGBAO PHARMACEUTICAL CO., LTD.
13.25. Wockhardt Limited

14. Appendix
14.1. Discussion Guide
14.2. License & Pricing

List of Figures
FIGURE 1. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, 2020 VS 2026 (USD BILLION)
FIGURE 2. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2020 (USD BILLION)
FIGURE 3. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2020 (USD BILLION)
FIGURE 4. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2020 (USD BILLION)
FIGURE 5. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY REGION, 2020 (USD BILLION)
FIGURE 6. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 7. GLOBAL ANTIDIABETIC DRUG MARKET: MARKET DYNAMICS
FIGURE 8. GLOBAL ANTIDIABETIC DRUG MARKET: PORTERS FIVE FORCES ANALYSIS
FIGURE 9. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2020 VS 2026 (%)
FIGURE 10. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2020 VS 2026 (USD BILLION)
FIGURE 11. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2026
FIGURE 12. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY ADULT, 2018-2026 (USD BILLION)
FIGURE 13. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY ADULT, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 14. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY GERIATRIC, 2018-2026 (USD BILLION)
FIGURE 15. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY GERIATRIC, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 16. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY PEDIATRIC, 2018-2026 (USD BILLION)
FIGURE 17. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY PEDIATRIC, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 18. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2020 VS 2026 (%)
FIGURE 19. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2020 VS 2026 (USD BILLION)
FIGURE 20. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2026
FIGURE 21. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY ALPHA-GLUCOSIDASE INHIBITORS, 2018-2026 (USD BILLION)
FIGURE 22. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY ALPHA-GLUCOSIDASE INHIBITORS, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 23. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY BIGUANIDES, 2018-2026 (USD BILLION)
FIGURE 24. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY BIGUANIDES, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 25. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DPP-IV (DIPEPTIDYL PEPTIDASE) INHIBITORS, 2018-2026 (USD BILLION)
FIGURE 26. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DPP-IV (DIPEPTIDYL PEPTIDASE) INHIBITORS, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 27. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY GLP-1 (GLUCAGON-LIKE PEPTIDE) AGONISTS, 2018-2026 (USD BILLION)
FIGURE 28. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY GLP-1 (GLUCAGON-LIKE PEPTIDE) AGONISTS, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 29. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY INSULIN, 2018-2026 (USD BILLION)
FIGURE 30. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY INSULIN, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 31. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY INTERMEDIATE-ACTING INSULIN, 2018-2026 (USD BILLION)
FIGURE 32. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY INTERMEDIATE-ACTING INSULIN, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 33. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY LONG-ACTING ANALOG, 2018-2026 (USD BILLION)
FIGURE 34. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY LONG-ACTING ANALOG, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 35. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY PREMIXED INSULIN, 2018-2026 (USD BILLION)
FIGURE 36. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY PREMIXED INSULIN, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 37. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY RAPID-ACTING ANALOG, 2018-2026 (USD BILLION)
FIGURE 38. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY RAPID-ACTING ANALOG, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 39. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY SHORT-ACTING ANALOG, 2018-2026 (USD BILLION)
FIGURE 40. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY SHORT-ACTING ANALOG, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 41. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY MEGLITINIDES, 2018-2026 (USD BILLION)
FIGURE 42. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY MEGLITINIDES, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 43. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY SGLT-II (SODIUM GLUCOSE TRANSPORT PROTEINS) INHIBITORS, 2018-2026 (USD BILLION)
FIGURE 44. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY SGLT-II (SODIUM GLUCOSE TRANSPORT PROTEINS) INHIBITORS, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 45. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY SULPHONYLUREAS, 2018-2026 (USD BILLION)
FIGURE 46. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY SULPHONYLUREAS, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 47. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY THIAZOLIDINEDIONE, 2018-2026 (USD BILLION)
FIGURE 48. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY THIAZOLIDINEDIONE, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 49. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2020 VS 2026 (%)
FIGURE 50. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2020 VS 2026 (USD BILLION)
FIGURE 51. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2026
FIGURE 52. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DIABETES MELLITUS TYPE 1, 2018-2026 (USD BILLION)
FIGURE 53. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DIABETES MELLITUS TYPE 1, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 54. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DIABETES MELLITUS TYPE 2, 2018-2026 (USD BILLION)
FIGURE 55. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DIABETES MELLITUS TYPE 2, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 56. AMERICAS ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 57. ARGENTINA ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 58. BRAZIL ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 59. CANADA ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 60. MEXICO ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 61. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 62. ASIA-PACIFIC ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 63. AUSTRALIA ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 64. CHINA ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 65. INDIA ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 66. INDONESIA ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 67. JAPAN ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 68. MALAYSIA ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 69. PHILIPPINES ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 70. SINGAPORE ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 71. SOUTH KOREA ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 72. THAILAND ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 73. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 74. FRANCE ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 75. GERMANY ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 76. ITALY ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 77. NETHERLANDS ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 78. QATAR ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 79. RUSSIA ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 80. SAUDI ARABIA ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 81. SOUTH AFRICA ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 82. SPAIN ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 83. UNITED ARAB EMIRATES ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 84. UNITED KINGDOM ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 85. GLOBAL ANTIDIABETIC DRUG MARKET: FPNV POSITIONING MATRIX
FIGURE 86. GLOBAL ANTIDIABETIC DRUG MARKET: SHARE, BY KEY PLAYER, 2020
FIGURE 87. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL ANTIDIABETIC DRUG MARKET, BY TYPE

List of Tables
TABLE 1. GLOBAL ANTIDIABETIC DRUG MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016–2020
TABLE 3. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 4. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2018-2026 (USD BILLION)
TABLE 5. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY ADULT, BY REGION, 2018-2026 (USD BILLION)
TABLE 6. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2026 (USD BILLION)
TABLE 7. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2026 (USD BILLION)
TABLE 8. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD BILLION)
TABLE 9. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY ALPHA-GLUCOSIDASE INHIBITORS, BY REGION, 2018-2026 (USD BILLION)
TABLE 10. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY BIGUANIDES, BY REGION, 2018-2026 (USD BILLION)
TABLE 11. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DPP-IV (DIPEPTIDYL PEPTIDASE) INHIBITORS, BY REGION, 2018-2026 (USD BILLION)
TABLE 12. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY GLP-1 (GLUCAGON-LIKE PEPTIDE) AGONISTS, BY REGION, 2018-2026 (USD BILLION)
TABLE 13. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY INSULIN, BY REGION, 2018-2026 (USD BILLION)
TABLE 14. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY INTERMEDIATE-ACTING INSULIN, BY REGION, 2018-2026 (USD BILLION)
TABLE 15. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY LONG-ACTING ANALOG, BY REGION, 2018-2026 (USD BILLION)
TABLE 16. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY PREMIXED INSULIN, BY REGION, 2018-2026 (USD BILLION)
TABLE 17. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY RAPID-ACTING ANALOG, BY REGION, 2018-2026 (USD BILLION)
TABLE 18. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY SHORT-ACTING ANALOG, BY REGION, 2018-2026 (USD BILLION)
TABLE 19. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY MEGLITINIDES, BY REGION, 2018-2026 (USD BILLION)
TABLE 20. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY SGLT-II (SODIUM GLUCOSE TRANSPORT PROTEINS) INHIBITORS, BY REGION, 2018-2026 (USD BILLION)
TABLE 21. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY SULPHONYLUREAS, BY REGION, 2018-2026 (USD BILLION)
TABLE 22. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY THIAZOLIDINEDIONE, BY REGION, 2018-2026 (USD BILLION)
TABLE 23. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE, 2018-2026 (USD BILLION)
TABLE 24. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DIABETES MELLITUS TYPE 1, BY REGION, 2018-2026 (USD BILLION)
TABLE 25. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DIABETES MELLITUS TYPE 2, BY REGION, 2018-2026 (USD BILLION)
TABLE 26. AMERICAS ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 27. ARGENTINA ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 28. BRAZIL ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 29. CANADA ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 30. MEXICO ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 31. UNITED STATES ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 32. ASIA-PACIFIC ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 33. AUSTRALIA ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 34. CHINA ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 35. INDIA ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 36. INDONESIA ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 37. JAPAN ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 38. MALAYSIA ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 39. PHILIPPINES ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 40. SINGAPORE ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 41. SOUTH KOREA ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 42. THAILAND ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 43. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 44. FRANCE ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 45. GERMANY ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 46. ITALY ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 47. NETHERLANDS ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 48. QATAR ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 49. RUSSIA ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 50. SAUDI ARABIA ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 51. SOUTH AFRICA ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 52. SPAIN ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 53. UNITED ARAB EMIRATES ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 54. UNITED KINGDOM ANTIDIABETIC DRUG MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 55. GLOBAL ANTIDIABETIC DRUG MARKET: SCORES
TABLE 56. GLOBAL ANTIDIABETIC DRUG MARKET: BUSINESS STRATEGY
TABLE 57. GLOBAL ANTIDIABETIC DRUG MARKET: PRODUCT SATISFACTION
TABLE 58. GLOBAL ANTIDIABETIC DRUG MARKET: RANKING
TABLE 59. GLOBAL ANTIDIABETIC DRUG MARKET: SHARE, BY KEY PLAYER, 2020
TABLE 60. GLOBAL ANTIDIABETIC DRUG MARKET: MERGER & ACQUISITION
TABLE 61. GLOBAL ANTIDIABETIC DRUG MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 62. GLOBAL ANTIDIABETIC DRUG MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 63. GLOBAL ANTIDIABETIC DRUG MARKET: INVESTMENT & FUNDING
TABLE 64. GLOBAL ANTIDIABETIC DRUG MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 65. GLOBAL ANTIDIABETIC DRUG MARKET: LICENSE & PRICING
Note: Product cover images may vary from those shown
  • Abbott Laboratories
  • Aristo Pharmaceuticals Pvt. Ltd.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Biocon Limited
  • C.H. Boehringer Sohn AG & Co. KG
  • Cadila Pharmaceuticals Limited
  • Cipla, Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Ltd.
  • Halozyme Therapeutics, Inc.
  • Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals)
  • Mankind Pharma Ltd
  • Merck KGaA
  • Novo Nordisk A/S
  • Oramed Pharmaceuticals Inc.
  • Pfizer Inc.
  • PHC Corporation
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • TONGHUA DONGBAO PHARMACEUTICAL CO., LTD.
  • Wockhardt Limited
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll